Board Of Directors – The FH Foundation
Stacey R. Lane, JD, MBE
Chairman of the Board
Stacey Lane is a graduate of the University of Pennsylvania and received her J.D. from Fordham University School of Law. Additionally, she received a Master’s Degree in Bioethics from Penn, with a concentration in public policy and regulation of new medical technologies. In addition to her work with the FH Foundation, Stacey is a member of the Board of Trustees of Montefiore Hospital in the Bronx, and is working on several bioethics initiatives in the New York area. She is also on the Advisory Council of the Hastings Center and is a member of the Advisory Board of the Bioethics Masters Program at Columbia University. Having been diagnosed with FH when she was 8, Stacey was originally treated at Rockefeller University in New York in the 1960s in some of the first cholesterol studies and has been monitored consistently since that time. She is the mother of three sons, two of whom also have FH.
Daniel J. Rader, MD
Dr. Rader is the Seymour Gray Professor of Molecular Medicine at the Perelman School of Medicine at the University of Pennsylvania. He serves as the Chair of the Department of Genetics as well as the Chief of the Division of Translational Medicine and Human Genetics in the Department of Medicine. He is also Associate Director of Penn’s Institute for Translational Medicine and Therapeutics.
Dr. Rader’s research focuses on the human genetics and functional genomics of lipoprotein metabolism and atherosclerosis, as well as the translational implications for novel therapeutic approaches. He led the scientific and clinical development of a first-in-class inhibitor of microsomal transfer protein for the treatment of severe hypercholesterolemia, which is now on the market. He has a particular interest in HDL metabolism and function, and novel approaches to targeting HDL metabolism and reverse cholesterol transport in the treatment, prevention, and regression of atherosclerosis.
Dr Rader trained in internal medicine at Yale-New Haven Hospital and in human genetics and physiology of lipoprotein metabolism at the National Institutes of Health. He has been on the Penn faculty since 1994. Dr. Rader is a member of the American Society of Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the National Academy of Sciences. He is a recipient of several awards including the Clinical Research Award from the American Heart Association.
Michael D. Shapiro, DO
Dr Shapiro is the inaugural Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest University where he is faculty in the Section of Cardiovascular Medicine. After completing a cardiology fellowship, he spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital/Harvard Medical School. After training, he was on the faculty in the Knight Cardiovascular Institute at Oregon Health & Science University. There, Shapiro was able to combine his interests in atherosclerosis imaging and prevention of cardiovascular disease. He was Director of Atherosclerosis imaging and Associate Director of the Center for Preventive Cardiology. His clinical interests focus on genetic and acquired disorders of cholesterol and triglycerides, atherosclerosis Imaging, genetic predisposition to early heart attacks, and cardiovascular risk assessment in apparently healthy individuals. Shapiro is now Director of the Center for Preventive Cardiology at Wake Forest Baptist Health.His work has been published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology. My current investigative research focuses on PCSK9 physiology and its impact on lipoprotein metabolism. Additionally, he is engaged in clinical trials testing novel lipid modulating therapeutics.
Allison serves the FH Foundation as a volunteer FH Advocate for Awareness and as a Board Member. She earned her BS in Commerce from the University of Virginia, and her MBA from the University of Texas at Austin. She currently works as the director of recruitment and marketing for the Daytime MBA and MMS programs at Duke Fuqua School of business.
Joshua W. Knowles, MD, PhD
Chief Research Advisor
Dr. Joshua W. Knowles is an Attending Physician in the Stanford Center for Inherited Cardiovascular Disease where he treats patients with Familial Hypercholesterolemia (FH). He has had a longstanding interest in the genetic (inherited) basis of cardiovascular disease and in particular the use modern genetic techniques to improve our ability to diagnose and treat patients at risk of heart disease. Dr. Knowles completed his MD-PhD at the University of North Carolina at Chapel Hill where he worked in the lab of Prof. Nobuyo Maeda and Nobel Laureate Oliver Smithies studying animal models of atherosclerosis and lipid metabolism. He then completed his Internal Medicine residency and Cardiovascular Medicine fellowship training at Stanford University working in the lab of Dr. Thomas Quertermous. He has published over 35 papers focused on heart disease with research projects currently funded by the National Institutes of Health and the American Heart Association. He is particularly excited to be involved with the FH Foundation in their mission to increase awareness of this condition, identify patients with FH, encourage screening of family members of those with FH and facilitate treatment of FH patients. He views FH as a “winnable battle” because once FH is identified, it can be usually be treated quite effectively. Josh and his wife Juliet live in Palo Alto with their daughter.
William A. Neal, MD
William A. Neal, MD, a native of Huntington, WV, earned his undergraduate degree from Xavier University in Cincinnati, Ohio in 1962. His medical degree was awarded by West Virginia University in 1966, where he was the first recipient of the Edward J. Van Liere Award for medical student research. From 1985 to 1998 he served as Chair of the WVU Department of Pediatrics. Dr. Neal was instrumental in the conceptualization and development of WVU Children’s Hospital and served as its first Medical Director. Dr. Neal is currently James H. Walker Professor of Preventive Cardiology in the Department of Pediatrics at West Virginia University.
Upon graduation from medical school, Dr. Neal continued training as a rotating intern at the Milwaukee County General Hospital, Marquette University, 1966-’67. He was then commissioned in the U.S. Navy, where after graduation from the Naval Aerospace Medical Institute, he was assigned as Flight Surgeon aboard the USS Constellation. He made two combat tours to Vietnam.
Postgraduate education in his chosen specialty of pediatric cardiology was accomplished at the University of Minnesota 1970-74. Dr. Neal then joined the faculty at WVU. He was awarded Emeritus status July 1, 2014 after forty years of service to the University and State.
Neal’s clinical career at WVU focused on development and regionalization of newborn intensive care, establishment of a statewide system of outreach clinics in pediatric cardiology, and founding of the Coronary Artery Risk Detection In Appalachian Communities (CARDIAC) Project. CARDIAC has provided risk factor surveillance, intervention, and research for over 150,000 school-age children from every West Virginia Community over the past sixteen years. As the largest comprehensive accumulation of health status data on children in the nation it has strongly influenced policy guidelines of the American Academy of Pediatrics regarding blood cholesterol screening and treatment for children at risk for premature heart disease and diabetes. He currently serves on the Board of Directors of the Familial Hypercholesterolemia Foundation.
He was named Distinguished Alumnus of the WVU School of Medicine in 2006.
Barry A. Brooks, JD
Barry Brooks is a partner of Paul Hastings, LLP, an international law firm with approximately 1,000 attorneys, and has practiced with that firm for 35 years, starting in the Los Angeles and Santa Monica, California offices, and moving to New York City in 1990. Mr. Brooks is currently the Chair the New York Office of the Firm – which at 275 attorneys is the Firm’s largest. Mr. Brooks represents parties in a variety of complex transactions and is the chair of the firm’s New York office and a partner in its Corporate Department. He represents parties in a broad range of public and private domestic and international mergers and acquisitions, private equity, corporate finance and joint venture transactions. Mr. Brooks represents private equity funds, hedge funds and other private investment funds and institutional investors and private and public operating companies in various industries. Mr. Brooks also advises public companies and their boards and committees in connection with corporate responsibility, fiduciary duty, disclosure and executive employment matters.
Mr. Brooks is the Vice Chair and a board member of the Tennis Foundation Of Connecticut, which has sponsored the annual Connecticut Open tennis tournament since 1989 and sponsors multiple programs to promote women’s causes and local youth access to tennis and other sports programs.
Mr. Brooks is a member of the State Bars of New York and California and of the American Bar Association. Mr. Brooks received his A.B. degree, summa cum laude, Phi Beta Kappa, in 1978 from the University of California at Los Angeles and his J.D. degree, cum laude, in 1981 from Harvard Law School, cum laude.
Katherine A. Wilemon
Katherine’s own journey to receive an accurate diagnosis and appropriate care for Familial Hypercholesterolemia (FH) urged her to devote her life to this cause. After being turned away from the ER several times and having a heart attack at 38, Katherine set out to raise awareness of FH and save lives. Katherine has spoken to thousands of people across the US and Europe in her effort to bring FH into focus, both for the public and the medical community. In the U.S. alone there are more than 1.3 million people affected by FH, yet 90% of them are undiagnosed. With the formation of The FH Foundation in 2011, Katherine’s goals are to reverse the shocking statistics and empower people with FH to have longer, healthier lives.